Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|December 10, 2007
New trials may cut clopidogrel use
A trio of late-breaking clinical trials could change standard drug treatment for patients undergoing percutaneous coronary intervention, or PCI.
Advertisement
Advertisement
Related to this article
A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
A guide built from conversations with pharmacists on social media and independent pharmacy owners.
Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.
Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.
Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
2
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
3
Generic Drug Costs Burdening Patients as Much as Brand Name Options
4
Social Media Best Practices for Pharmacists: Why Visibility Matters
5